The enclosure of the human body has reached its newest frontier with the FDA’s approval of 'Wegovy HD.' This high-dose semaglutide injection, patented by Novo Nordisk, promises a 20.7% reduction in body weight for those who can afford the premium price tag. While the US professional class celebrates this 'stronger metabolic push,' a stark divide is opening between the metabolic elite and the rest of humanity. In the United States, the drug remains gated behind a $350 monthly paywall on the administration’s direct-to-consumer marketplace, while in the Global South, manufacturers are forced to fight for $15 generic alternatives to address the same crisis.

This metabolic divide is the ultimate expression of corporate feudalism. By patenting the regulation of human hunger, firms like Novo Nordisk and Eli Lilly are effectively taxing the biological functions of the poor. As Novo Nordisk prepares global trials in China for its next-generation 'triple G' candidates, the goal is not the eradication of obesity but the maximization of yield from the chronic illness of the wealthy. The body itself is being mapped, segmented, and rented back to us in high-definition doses.

Simultaneously, the 'neural frontier' is being commercialized. With China approving the first implantable Brain-Computer Interface for paralyzed patients and researchers developing salt-grain-sized sensors to track dopamine, the mind is becoming a site of extraction. We are entering an era where our very thoughts and metabolic rates are no longer our own, but are instead proprietary data points managed by a 'living pharmacy' of sub-dermal implants. The medical-industrial complex is no longer curing us; it is colonizing us.